Floatz logo

2-(5-((3-ETHOXY-2-PYRIDYL)OXY)-3-PYRIDYL)-N-((3S,5S)-5-FLUORO-3-PIPERIDYL)PYRIMIDINE-5-CARBOXAMIDE

Liver Fibrosis

PfizerSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Liver Fibrosis cohort.

Asset / SponsorPhaseRating
Entecavir
Tanta University
Phase 4BB
COLCHICINUM
Zagazig University
Phase 4BB
Peg-Intron
Beth Israel Deaconess Medical Center
Phase 4BB
Peg-Ifn
Beijing Friendship Hospital
Phase 4BB
Hydronidone
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

2-(5-((3-ETHOXY-2-PYRIDYL)OXY)-3-PYRIDYL)-N-((3S,5S)-5-FLUORO-3-PIPERIDYL)PYRIMIDINE-5-CARBOXAMIDE is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →